Eli Lilly & Co. (LLY)

105.85
0.30 0.28
NYSE : Health Technology
Prev Close 105.55
Open 105.67
Day Low/High 105.58 / 106.38
52 Wk Low/High 73.69 / 105.92
Volume 406.74K
Avg Volume 3.57M
Exchange NYSE
Shares Outstanding 1.07B
Market Cap 112.08B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (2.10%)

Latest News

Elanco Animal Health Announces Pricing Of $2.0 Billion Of Senior Notes

Elanco Animal Health Announces Pricing Of $2.0 Billion Of Senior Notes

INDIANAPOLIS, Aug. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health Incorporated, has priced a private offering of $2.

Eli Lilly Breaks Out of a Large Consolidation Pattern, Further Gains Ahead

Eli Lilly Breaks Out of a Large Consolidation Pattern, Further Gains Ahead

The weekly breakout is pretty impressive on the charts, so let's take a look.

Jim Cramer: 4 Pet-Related Stocks That Are Top Dog

Jim Cramer: 4 Pet-Related Stocks That Are Top Dog

The humanization of pets theme is driving outstanding earnings and share price growth for these 4 names.

Elanco Animal Health Files IPO Registration Statement

Elanco Animal Health Files IPO Registration Statement

INDIANAPOLIS, Aug. 2, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health, has filed a registration statement with the U.

Healthcare Bulls Are Feeling Great After Earnings

Healthcare Bulls Are Feeling Great After Earnings

Investors may have been betting that the 'drug pricing war' was a non-event and that the upcoming earnings cycle would show continued growth and profitability in the healthcare sector.

Initiating Position in Amgen; Adding Again to Anadarko; Upgrading Kohl's

We are bringing AMGN out of the Bullpen and into the portfolio.

Lilly Diabetes Solution Center Now Open To Help People With Insulin Affordability

Lilly Diabetes Solution Center Now Open To Help People With Insulin Affordability

Starting today, people can dial (833) 808-1234 to access potential cost savings on Lilly insulins

Tech Rotation Hits Market; Bullpen Update

We are looking at today's rotation as an opportunity to pick up a high-quality name at a discount.

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.

Lilly Announces Extension Of Cancer Research Collaboration With Dana-Farber Cancer Institute

Lilly Announces Extension Of Cancer Research Collaboration With Dana-Farber Cancer Institute

Extension of research collaboration focused on enhancing and speeding the process of bringing new and advanced treatments to cancer patients

LLY: Insiders Vs. Shorts

LLY: Insiders Vs. Shorts

The most recent short interest data was recently released for the 07/13/2018 settlement date, and Lilly (Eli) & Co is the #187 most shorted of the S&P 500 components, based on 4.67 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.

Jim Cramer: We've Got an Extremist Market

Jim Cramer: We've Got an Extremist Market

Don't buy up when there's nothing but rampant pin action.

Dow Breaks 3-Day Skid; Nasdaq Rebounds to End Flat

Dow Breaks 3-Day Skid; Nasdaq Rebounds to End Flat

The Dow ended higher, breaking a 3-day skid, while the Nasdaq rebounded to end little changed after hitting a record high earlier.

Alphabet Isn't the Only Company With an Earnings Blowout - Here's the Rundown

Alphabet Isn't the Only Company With an Earnings Blowout - Here's the Rundown

Harley-Davidson, Verizon and other big hitters also reported earnings before Tuesday's opening bell.

Eli Lilly Shares Climb on Earnings Beat

Eli Lilly Shares Climb on Earnings Beat

The Indianapolis-based pharmaceutical giant unveils second-quarter results that surpass analysts' top- and bottom-line estimates.

3 Ways to Play Facebook Ahead of Wednesday's Earnings

3 Ways to Play Facebook Ahead of Wednesday's Earnings

Here are some options strategies for this FANG name into tomorrow's report.

Alphabet, AT&T, Verizon and New York Daily News - 5 Things You Must Know

Alphabet, AT&T, Verizon and New York Daily News - 5 Things You Must Know

U.S. stock futures rise on Tuesday, with solid corporate earnings boosting shares on Wall Street; Alphabet is set to open at a record high after the parent of Google posts a significant earnings beat; AT&T and Verizon highlight Tuesday's earnings calendar.

Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance

Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance

- Second-quarter 2018 revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products, while operating expenses declined.

Lilly To Separate Elanco Animal Health With Initial Public Offering

Lilly To Separate Elanco Animal Health With Initial Public Offering

INDIANAPOLIS, July 24, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the U.

Last Week's Portfolio Changes

We raised our price targets on four positions after their latest earnings reports.

Exiting Eli Lilly Position

We are taking a win, closing our LLY position and minimizing risk just a few days before it reports second-quarter earnings.

Highlights From Lilly's Alzheimer's Disease Pipeline At The Alzheimer's Association International Conference® 2018 (AAIC® 2018)

Highlights From Lilly's Alzheimer's Disease Pipeline At The Alzheimer's Association International Conference® 2018 (AAIC® 2018)

INDIANAPOLIS, July 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association International...

Study Published In The Lancet Shows Benefit Of Baricitinib 4 Mg For The Treatment Of Systemic Lupus Erythematosus (SLE)

Study Published In The Lancet Shows Benefit Of Baricitinib 4 Mg For The Treatment Of Systemic Lupus Erythematosus (SLE)

INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet.

Boehringer Ingelheim And Lilly Announce Tradjenta's CARMELINA® Cardiovascular Outcome Trial Meets Primary Endpoint

Boehringer Ingelheim And Lilly Announce Tradjenta's CARMELINA® Cardiovascular Outcome Trial Meets Primary Endpoint

- Study supports long-term cardiovascular safety of Tradjenta® (linagliptin) in adults with type 2 diabetes

Selling Some Eli Lilly to Lock in Profits

We're trimming the position at our highest sale price to date.

TheStreet Quant Rating: B (Buy)